Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
- PMID: 26835516
- PMCID: PMC4729387
- DOI: 10.1016/S2055-6640(20)30482-9
Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
Abstract
Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and immune activation.
Methods: Thai patients with Fiebig I-IV AHI were prospectively enrolled and offered treatment. They were randomised 1:1 to HAART (tenofovir/emtricitabine/efavirenz, n =31) or megaHAART, a standard regimen intensified by raltegravir/maraviroc (n =31), during the first 24 weeks of therapy. Participants were monitored at weeks 0, 2, 4, 8 and 12, then every 12 weeks. Frequencies of peripheral blood mononuclear cells (PBMCs) carrying HIV DNA (total, integrated and 2-LTR episomes), plasma C-reactive protein (CRP) concentrations, and frequencies of activated T cells were measured. Flexible sigmoidoscopy was performed in willing participants (n =25) at baseline, weeks 24 and 96, and proviral DNA and RNA were determined.
Results: Baseline characteristics were similar in the HAART and megaHAART arms. Median age was 28 years and 95% were men. Median CD4 cell count was 388 cells/mm3. HIV RNA was 5.6 log10 copies/mL. HIV RNA declined more rapidly in the first 4 weeks with megaHAART (median -3.3 log10) than HAART (-2.6 log10). Time to achieve HIV RNA <50 copies/mL was shorter with megaHAART (median 55 days) than HAART (83 days, P =0.04). Viral suppression rates after week 12 did not differ between arms, and overall, 97% achieved suppression by week 48. The frequency of cells harbouring total HIV DNA was similarly low after 96 weeks in both treatment arms (median of 7 and 4 copies/106 PBMCs in the megaHAART and HAART arms, respectively, P =0.41). At weeks 2 and 12, frequency of cells carrying 2-LTR circles were significantly higher with megaHAART (P =0.03). In the sigmoid colon, total HIV DNA and HIV RNA declined after treatment, with no differences between arms. The frequencies of cells with 2-LTR circles were also higher in the sigmoid colon at week 24 with megaHAART. Plasma levels of CRP and frequencies of CD4+ and CD8+ T cells expressing CD38 and HLA-DR or Ki67 were similar between arms.
Conclusions: Intensification of standard HAART with raltegravir and maraviroc was not associated with either statistically significant reductions of markers of HIV reservoir size in blood and sigmoid colon or markers of immune activation in blood.
Keywords: ART; Acute HIV infection; HIV DNA; immune activation; maraviroc; raltegravir; reservoir.
Figures






Similar articles
-
Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.PLoS One. 2012;7(3):e33948. doi: 10.1371/journal.pone.0033948. Epub 2012 Mar 30. PLoS One. 2012. PMID: 22479485 Free PMC article.
-
Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.AIDS Res Ther. 2014 Oct 7;11(1):33. doi: 10.1186/1742-6405-11-33. eCollection 2014. AIDS Res Ther. 2014. PMID: 25320633 Free PMC article.
-
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066. AIDS. 2014. PMID: 24185044 Clinical Trial.
-
Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.Retrovirology. 2018 Jan 30;15(1):15. doi: 10.1186/s12977-018-0398-1. Retrovirology. 2018. PMID: 29378611 Free PMC article. Review.
-
Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Drugs. 2010. PMID: 20731472 Review.
Cited by
-
Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.J Infect Dis. 2017 Mar 15;215(suppl_3):S111-S118. doi: 10.1093/infdis/jiw618. J Infect Dis. 2017. PMID: 28520964 Free PMC article. Review.
-
HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy.J Clin Invest. 2019 Jul 30;129(11):4629-4642. doi: 10.1172/JCI126714. J Clin Invest. 2019. PMID: 31361603 Free PMC article. Clinical Trial.
-
Post-Treatment Controllers: Role in HIV "Cure" Research.Curr HIV/AIDS Rep. 2016 Feb;13(1):1-9. doi: 10.1007/s11904-016-0296-x. Curr HIV/AIDS Rep. 2016. PMID: 26781112 Review.
-
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.Sci Rep. 2017 May 24;7(1):2385. doi: 10.1038/s41598-017-02634-y. Sci Rep. 2017. PMID: 28539614 Free PMC article.
-
Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring.Adv Drug Deliv Rev. 2016 Aug 1;103:90-104. doi: 10.1016/j.addr.2016.05.018. Epub 2016 Jun 2. Adv Drug Deliv Rev. 2016. PMID: 27262924 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous